Longer anticoagulation cuts repeat clot risk in isolated distal DVT: study
Prolonging anticoagulation doesn’t increase the risk of major bleeding events, researchers say
Doubling the duration of rivaroxaban therapy cuts the long-term risk of recurrent thrombotic events in patients with isolated distal DVT without increasing the risk of major bleeds, research shows.
Compared to adults given placebo after an “uneventful” six-weeks of anticoagulation, Italian doctors say a 12-week regimen of rivaroxaban safely reduces the risk of further VTE by almost half over two years.
